| Followers | 200 |
| Posts | 25597 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Saturday, November 27, 2021 6:25:17 PM
I can’t agree on the personal profit argument AHP. 1) the contract payments are cost plus a very minor and reasonable amount; 2) the company owns the assets; 3) other than construction, not a lot of contract manufacturing is going on right now but all of those people are on the Advent payroll regardless; and 4) I believe it is the fund that has shares in Advent, and that is not all her money necessarily, just a private equity investment vehicle.
So, Advent does not have a factory and does not appear to have a lot of other business. It has a substantial payroll, and she is not the direct personal owner, and the fact that she may or may not have control over the fund, does not mean she is personally benefitting or getting any cash from there.
Cognate is not directly comparable; 1) the executives in cognate took it over before the sale to CRL, I do not believe she owned a huge amount there when they did the buyout, but if she did, it was definitely not a controlling interest because it had already gone through a management buyout. And she was not a manager.
She is also NOT a manager at Advent, so no salary.
It sounds good to draw everything together like it is a big conspiracy with here a giant spider in the middle, but a) that is what shorts tell people; and b) it is a boogey man’s story. It does not appear to actually be true when you look at the details. There are connections, but the stories, the crazy suggestions that some make honestly, do not appear to be there to me. It seems rather that she is a guiding force behind different entities holding this effort together, but personal profit does not look like the primary driver and if it were, it would be a lot more open and obvious.
There is a whole segment of traders who have been selling this story for years, periodically, and that’s the narrative they like to sell. But again, it does not appear to be accurate beyond the superficial links.
So, Advent does not have a factory and does not appear to have a lot of other business. It has a substantial payroll, and she is not the direct personal owner, and the fact that she may or may not have control over the fund, does not mean she is personally benefitting or getting any cash from there.
Cognate is not directly comparable; 1) the executives in cognate took it over before the sale to CRL, I do not believe she owned a huge amount there when they did the buyout, but if she did, it was definitely not a controlling interest because it had already gone through a management buyout. And she was not a manager.
She is also NOT a manager at Advent, so no salary.
It sounds good to draw everything together like it is a big conspiracy with here a giant spider in the middle, but a) that is what shorts tell people; and b) it is a boogey man’s story. It does not appear to actually be true when you look at the details. There are connections, but the stories, the crazy suggestions that some make honestly, do not appear to be there to me. It seems rather that she is a guiding force behind different entities holding this effort together, but personal profit does not look like the primary driver and if it were, it would be a lot more open and obvious.
There is a whole segment of traders who have been selling this story for years, periodically, and that’s the narrative they like to sell. But again, it does not appear to be accurate beyond the superficial links.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
